Czechia· CZ-0025490

FASTURTEC

A rasburicase product containing rasburicase, registered in Czechia by Sanofi Winthrop Industrie, Gentilly. The same ATC class is registered in 13 of our 19 countries.

ATC V03AF07

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedFASTURTECATCV03AF07REGISTER NO.CZ-0025490PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Rasburicase is registered in 13 of 19 countries.

Countries holding a registration under ATC V03AF07 (rasburicase), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose

Rasburicase · ATC V03AF07

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
RASBURICASE
Manufacturer
Sanofi Winthrop Industrie, Gentilly
Country
Czechia (CZ)
ATC code
V03AF07
ATC class
Rasburicase
Defined daily dose
14 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for rasburicase.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rasburicase · interactions on record

25 records

  • 1 severe
  • 24 moderate

Most severe, free to view

  • PrilocaineN01BB04severe
  • LidocainA01AE01moderate
  • TetracainA01AE02moderate
  • LidocaineC05AD01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e60874fa-5bec-40db-991b-c664b52ef5d1
GET /v1/drugs/e60874fa-5bec-40db-991b-c664b52ef5d1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF PLQ CSL",
  "source": "sukl",
  "strength": "1,5MG/ML",
  "pack_size": "1X7,5MG+1X5ML AMP",
  "substance": "RASBURICASE",
  "cz_kod_sukl": "0025490",
  "product_type": "BT",
  "substance_codes": "15832",
  "registration_state": "R",
  "registration_number": "EU/1/00/170/002"
}

See everything about rasburicase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.